I know many who are detractors from the skills of out management. I on the other hand have the belief that they're doing a great job of bringing things together in a timely manner. The acquisition of Advent and creation of a leukapheresis facility are the latest examples. I don't know if they put far more money into FlaskWorks if the EDEN could have been developed faster, but they have identified where it can be operational practically as quickly as it's approved in both the UK and US without the expense of building the cleanroom.
I doubt if anyone outside the company, which includes FlaskWorks, knows all that's been done there to work toward an approve unit. If the people there believed that changes in the unit could prove beneficial, it sounds like they were permitted to try. A unit too large to fit through a door is only a problem if it can't be broken down and moved in, or out if necessary. The main question is what's the advantage of the larger size. If it takes as much space as two of the smaller unit's side by side, it will need to make vaccine in less than half the time of the smaller units. I have no idea how certain investors learned of this, but it appears like the large unit's been abandoned and they're proceeding. I've said all along that the EDEN's the key to multi-national approvals and it seems to be coming true. I believe we'll see the EDEN approved before the end of the year, with it I believe we'll learn of either multiple filings or an Orbis filing for multi-national approvals including the US.
Gary
Bullish
Market Data 
Markets 
AI
